

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/23050> holds various files of this Leiden University dissertation

**Author:** Klumpers, Linda

**Title:** Novel approaches in clinical development of cannabinoid drugs

**Issue Date:** 2014-01-21

---

## **CURRICULUM VITAE**

---

---

In 1980 I was born in Rotterdam. After finishing grammar school in 1999 at the Gymnasium Camphusianum in Gorinchem, I studied medical biology with a focus on neurobiology at the University of Amsterdam. After graduation (M.Sc.) in January 2004, travelling and working as a full-time musician, I worked as a project leader at the Centre for Human Drug Research from 2006 to 2011. The research described in this thesis was performed during that period. In 2010, I was awarded the Pre-doctoral student award at the International Cannabinoid Research Society conference in Lund, Sweden for my presentation of the results of ‘Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects’. For publication of this research, I was awarded the BJCP Prize in London in 2013. During my work at the CHDR, I was trained as a clinical pharmacologist. From 2012 to 2013, I worked as a senior business analyst at A.T. Kearney. In October 2013, I started as a business development manager at SkylineDx, a medical diagnostics company.

---

---

## PUBLICATION LIST

---

---

- Zheng G, Klumpers LE, Oyetayo B, Heuberger J, van Gerven JMA, Stevens J, Freijer JI, Pharmacokinetic/pharmacodynamic modelling and simulation of the effects of different CB1 antagonists on  $\Delta^9$ -tetrahydrocannabinol challenge tests in healthy volunteers, *submitted*
- Kleinloog D, Zoethout R, Klumpers L, Niesters M, Dahan A, Rombouts S, van Gerven J, Subjective effects of ethanol, morphine, tetrahydrocannabinol and ketamine following a pharmacological challenge are related to functional brain connectivity, *submitted*
- Klumpers LE, Fridberg M, de Kam ML, Little PB, Kleinloog HD, Elling CE, van Gerven JMA, Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects, *Br J Clin Pharmacol*, 2013;76 (6):846-57
- Klumpers LE, Roy C, Turpault S, Ferron G, Poitiers F, van Hasselt JGC, Zuurman L, Schoemaker RC, Erwich FAS, van Gerven JMA, Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits  $\Delta^9$ -tetrahydrocannabinol-induced central nervous system and heart rate effects in humans, *Br J Clin Pharmacol*, 2013;76 (1):65-77
- Klumpers LE, Soeter RP, Khalili-Mahani N, Te Beek ET, Rombouts SAR, van Gerven, JMA, Manipulating brain connectivity with  $\Delta^9$ -tetrahydrocannabinol: a pharmacological resting state fMRI study, *Neuroimage*, 15 November 2012, Volume 63, Issue 3, 1701-11
- Klumpers LE, Beumer TL, van Hasselt JGC, Lipplaa A, Karger LB, Kleinloog HD, de Kam ML, van Gerven JMA, Novel  $\Delta^9$ -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects, *Br J Clin Pharmacol*, July 2012, Volume 74, Issue 1, pages 42-53
- Mayer JL, Klumpers L, Maslam S, de Kloet ER, Joels M, Lucassen PJ, Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. *J Neuroendocrinol*, 2006, 18 (8):629-31

---

## ACKNOWLEDGEMENTS

---

Thank you, (former) colleagues, clients and partners of the CHDR for your cooperation, support and the opportunities that you gave to me for research performance, the making of this thesis and for professional and personal development.

Bedankt!

Linda Klumpers